25893
document
A crossover study of risperidone in children , adolescents and adults with mental retardation . Risperidone has shown safety and efficacy for aggressive and destructive behaviors in short-term studies . This longer-duration study includes a broad sample . Forty subjects , aged 8-56 years ( mean=22 ) , all with mental retardation and 36 with autism spectrum disorders participated in this 22-week crossover study , with 24 weeks of open maintenance thereafter . Of 40 subjects , 23 ( 57.5 % ) responded fully ( 50 % decrease in Aberrant Behavior Checklist-Community Irritability subscale score ) , while 35 subjects ( 87.5 % ) showed a 25 % decrease . Gender , mood disorder , and antiseizure medications did not alter response . Increased appetite and weight gain were common . Low dose risperidone was effective for aggressive behavior in persons with MR. More long-term studies are needed , incorporating weight control interventions .
25894
Intervention_Pharmacological
risperidone
25895
Intervention_Pharmacological
Risperidone
25896
Outcome_Other
safety and efficacy
25897
Outcome_Mental
Aberrant Behavior Checklist-Community Irritability subscale score
25898
Outcome_Physical
Increased appetite and weight gain
25899
Outcome_Mental
effective
25900
Outcome_Mental
aggressive behavior
25901
Participant_Condition
children , adolescents and adults with mental retardation .
25902
Participant_Condition
Forty subjects , aged 8-56 years ( mean=22 ) , all with mental retardation and 36 with autism spectrum disorders participated